The city of Omaha, Nebraska, currently has 8 active clinical trials seeking participants for Diabetes research studies.
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema 2.4... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Univ. of Nebraska Medical Center_Omaha, Omaha, Nebraska
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Recruiting
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar levels as compared to insulin glargine in people with type 2 diabetes who do not have their blood sugar properly controlled with other oral diabetes medicines. Participant will either get IcoSema or insu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Methodist Physicians Clinic Diabetes and Endocrinology Specialists, Omaha, Nebraska
Conditions: Type 2 Diabetes
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Recruiting
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec onc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Univ of Nebraska Medical CTR, Omaha, Nebraska +1 locations
Conditions: Diabetes, Type 2
Empagliflozin Treatment in Kidney Transplant Recipients
Recruiting
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress i... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
05/14/2024
Locations: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska
Conditions: Kidney Transplant, Type 2 Diabetes
Blood Markers of Early Pancreas Cancer
Recruiting
Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
Gender:
All
Ages:
19 years and above
Trial Updated:
02/20/2024
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
Recruiting
Patients with Type 1 Diabetes Mellitus (T1DM) have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone tissue mechanical defects. The potential benefits to participants would be knowledge gained about their bone density and the results of laboratory tests. On a wider scale, there may be general benefit... Read More
Gender:
Female
Ages:
50 years and above
Trial Updated:
08/16/2023
Locations: Creighton University Osteoporosis Research Center, Omaha, Nebraska
Conditions: Type 1 Diabetes, Osteopenia, Bone Loss, Fractures, Bone
Continuous Monitoring and Control of Hypoglycemia
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Methodist Physicians Clinic - Diabetes and Endocrine Specialists, Omaha, Nebraska
Conditions: Diabetes